Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Use of Herceptin and Chemotherapy Improves Survival in Early Stage Breast Cancer

09.12.2005


Pairing the targeted therapy Herceptin with chemotherapy in patients with early stage breast cancer significantly increases disease-free survival time in women who test positive for a genetic mutation that results in a particularly aggressive form of the disease, according to large, international study.



The study also tested Herceptin with a chemotherapy combination that eliminated Adriamycin, an anthracycline commonly used to treat breast cancer but a drug that, when used with Herceptin, can result in heart damage. That regimen also significantly improves survival.

Conducted by the Breast Cancer International Research Group (BCIRG), this study is the fourth large clinical trial to show that Herceptin plus chemotherapy significantly reduces risk of disease recurrence in early breast cancer. Results were presented Thursday at the San Antonio Breast Cancer Symposium by Dr. Dennis Slamon, co-chairman of BCIRG, director of Clinical/Translational Research at UCLA’s Jonsson Cancer Center and the scientist whose laboratory and clinical research laid the groundwork for the development of Herceptin.


"The chemotherapy combinations we tested with Herceptin proved to be superior to the best available standard therapy for early breast cancer," said Slamon, principal investigator for the BCIRG study. "This further illustrates the promise of targeted therapies and moves us closer to our goal of minimizing the toxicity of therapy while maximizing efficacy."

Herceptin is effective in women with HER-2 positive breast cancer, about one in four diagnosed with the disease every year. HER-2 positive breast cancer patients have a particularly aggressive form of the disease, a poorer prognosis and shorter survival times, said Slamon, who discovered the link between HER-2 positivity and aggressive breast cancer in 1987.

The study enrolled 3,222 women from all over the world with early stage HER-2 positive breast cancer between March 2001 and February 2004. Patients received one of three regimens:

* The standard therapy of Adriamycin and Carboplatin followed by Taxotere (ACT).
* An experimental regimen of Adriamycin and Carboplatin followed by Taxotere and one year of Herceptin (ACTH).
* An experimental regimen of Taxotere and Carboplatin with one year of Herceptin (TCH).

Reduction in risk of disease recurrence, the study’s primary endpoint, was 51 percent in the ACTH study arm and 39 percent in the TCH arm.

"This is very promising news for the 250,000 women worldwide, including 50,000 in the United States, who will be diagnosed every year with this aggressive breast cancer," Slamon said.

The BCIRG study also resulted in two other important findings. Researchers knew that giving Herceptin with Adriamycin resulted in heart damage in some patients, the most severe of which was congestive heart failure. It was theorized, however, that this damage was not long lasting. But the BCIRG study showed the cardiac toxicity was significant and still persisted for more than 18 months at the date of the last follow up, Slamon said. This is vital information for doctors and patients to have when deciding which treatment regimen to use.

Of the 3,222 patients in the study, 353 experienced a greater than 10 percent loss of heart function. Of those, 91 patients (9 percent) were enrolled in the ACT study arm; 82 patients (8 percent) were in the TCH arm; and 180 patients (17.3 percent) were in the ACTH arm, which paired Adriamycin with Herceptin.

"We’ve always known that the major safety problem with Herceptin has been cardiac toxicity when it is used with Adriamycin," Slamon said. "When breast cancer patients lose their hair, it grows back. When we suppress their bone marrow, that comes back, too. Heart failure, however, is a much larger problem, especially if it does not improve over time."

The good news, Slamon said, is that Herceptin given with the chemotherapy combination that eliminates Adriamycin is still significantly superior to the best available chemotherapy alone, reducing risk of relapse by 39 percent. That gives physicians and patients worried about heart damage an additional option.

The study’s other important finding is that a subset of HER-2 positive patients - about 35 percent - also have amplification of a gene called topo II, which makes them more likely to respond to Adriamycin. As Herceptin targets HER-2, Adriamycin targets topo II. Patients who test positive for amplification of both HER-2 and topo II might opt for the drug regimen with Adriamycin, risking heart damage in exchange for a better response to therapy.

Slamon said a test that indicates both HER-2 and topo II amplification is being developed so doctors will better be able to tell which patients should be on which drug regimen.

"Women will have the information they need to decide if the risk is worth the benefit," Slamon said.

At UCLA’s Jonsson Cancer Center, doctors are testing Herceptin in combination with other targeted therapies such as the angiogenesis inhibitor Avastin. That, Slamon said, may be the future of breast cancer therapy - the elimination of chemotherapy.

"In the future, we’re likely to come up with therapies that are very much improved over what we have now and offer maximum efficacy with little or no toxicity," Slamon said.

UCLA’s Jonsson Comprehensive Cancer Center comprises more than 240 researchers and clinicians engaged in research, prevention, detection, control, treatment and education. One of the nation’s largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating the results into leading-edge clinical studies. In July 2005, the Jonsson Cancer Center was named the best cancer center in the western United States by U.S. News & World Report, a ranking it has held for six consecutive years.

Kim Irwin | EurekAlert!
Further information:
http://www.mednet.ucla.edu

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>